Subscribe
handshake-1
miodrag ignjatovic / iStockphoto.com
10 May 2018Asia-Pacific

AstraZeneca sells Seroquel rights for $538m

AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Will Big Pharma get the bug for microbiome therapies?
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Americas
AstraZeneca sells US rights to four drugs for $46.5m
3 January 2018   AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Big Pharma
Will Big Pharma get the bug for microbiome therapies?
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Americas
AstraZeneca sells US rights to four drugs for $46.5m
3 January 2018   AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.

More on this story

Big Pharma
Will Big Pharma get the bug for microbiome therapies?
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Americas
AstraZeneca sells US rights to four drugs for $46.5m
3 January 2018   AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers